Cargando…

START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection

The Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) study has reinforced the benefits of early initiation of antiretroviral therapy (ART). However, a notable secondary finding from that study was that immediate initiation of ART did not prevent cardiovascular disease...

Descripción completa

Detalles Bibliográficos
Autor principal:	Siedner, Mark J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794943/ https://www.ncbi.nlm.nih.gov/pubmed/26989755 http://dx.doi.org/10.1093/ofid/ofw032

Ejemplares similares

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Persistent Immune Activation in Human Immunodeficiency Virus–Infected Pregnant Women Starting Combination Antiretroviral Therapy After Conception
por: Lohman-Payne, Barbara, et al.
Publicado: (2021)

Myocardial Inflammatory Changes Before and After Antiretroviral Therapy Initiation in People With Advanced Human Immunodeficiency Virus Disease
por: Piñeirua-Menéndez, A, et al.
Publicado: (2020)

Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis
por: Kay, Alexander, et al.
Publicado: (2022)

Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Idiculla, Jyothi, et al.
Publicado: (2018)

Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2019)

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial
por: Baker, Jason V., et al.
Publicado: (2017)

Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy
por: Daar, Eric S
Publicado: (2009)

Editorial Commentary: Immunodeficiency at Start of Antiretroviral Therapy: The Persistent Problem of Late Presentation to Care
por: Ford, Nathan, et al.
Publicado: (2015)

Efavirenz-metabolizing polymorphisms, viral suppression, and depression in HIV-infected individuals initiating antiretroviral therapy in southwestern Uganda
por: Chang, Jonathan, et al.
Publicado: (2017)

Adherence to antiretrovirals in people coinfected with the human immunodeficiency virus and tuberculosis
por: Lemos, Larissa de Araújo, et al.
Publicado: (2016)

Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010
por: Zhu, Hao, et al.
Publicado: (2012)

Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy
por: Salvadori, Nicolas, et al.
Publicado: (2017)

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)

‘I need time to start antiretroviral therapy’: understanding reasons for delayed ART initiation among people diagnosed with HIV in Lusaka, Zambia’
por: Mwamba, Chanda, et al.
Publicado: (2022)

Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa
por: Leroi, Charline, et al.
Publicado: (2017)

Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis
por: Kimaro, Godfather Dickson, et al.
Publicado: (2020)

Appropriate Time to Start Antiretroviral Therapy in HIV-infected Patients with Penicilliosis marneffei
por: Utkham, Thongchai, et al.
Publicado: (2017)

Effectiveness of same-day antiretroviral therapy initiation in retention outcomes among people living with human immunodeficiency virus in Ethiopia: empirical evidence
por: Ahmed, Ismael, et al.
Publicado: (2020)

Combination Antiretroviral Therapy and Immunophenotype of Feline Immunodeficiency Virus
por: Kim, Jeffrey, et al.
Publicado: (2023)

Epidemiology and Clinical Parameters of Adult Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome at the Initiation of Antiretroviral Therapy in South Eastern Nigeria
por: Eleje, GU, et al.
Publicado: (2014)

Association between Combination Antiretroviral Therapy and Telomere Length in People Living with Human Immunodeficiency Virus
por: Bukic, Ena, et al.
Publicado: (2023)

When to Start Antiretroviral Therapy
por: Jain, Vivek, et al.
Publicado: (2010)

Pulmonary toxoplasmosis in human immunodeficiency virus-infected patients in the era of antiretroviral therapy
por: Velásquez, Jorge N, et al.
Publicado: (2016)

Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus
por: Murenzi, Gad, et al.
Publicado: (2023)

Efficacy of Prompt Initiation of Antiretroviral Therapy in the Treatment of Hemophagocytic Lymphohistiocytosis Triggered by Uncontrolled Human Immunodeficiency Virus
por: Fitzgerald, Bryan P., et al.
Publicado: (2017)

At the crossroads between early or delayed antiretroviral therapy initiation during tuberculosis/human immunodeficiency virus coinfection
por: Moreira, José Alfredo de Sousa
Publicado: (2014)

Hypercalcemia during initiation of antiretroviral therapy in human immunodeficiency virus and Leishmania coinfection: A case report
por: Yu, Tammy, et al.
Publicado: (2023)

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Virologic outcomes of people living with human immunodeficiency virus who started antiretroviral treatment on the same-day of diagnosis in Ethiopia: A multicenter observational study
por: Ahmed, Ismael, et al.
Publicado: (2021)

Human immunodeficiency virus infection and cardiovascular risk
por: Zaharia-Kézdi, Erzsébet Iringó, et al.
Publicado: (2014)

Empiric Deworming and CD4 Count Recovery in HIV-Infected Ugandans Initiating Antiretroviral Therapy
por: Lankowski, Alexander J., et al.
Publicado: (2014)

Aging, neurocognitive impairment and adherence to antiretroviral therapy in human immunodeficiency virus-infected individuals
por: Pinheiro, Cezar Arthur Tavares, et al.
Publicado: (2016)

When Should Children with HIV Infection Be Started on Antiretroviral Therapy?
por: Welch, Steven B, et al.
Publicado: (2008)

Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
por: Benson, Carmela, et al.
Publicado: (2020)

1576. Implementation of a Pharmacist-Driven Initiation of Antiretroviral Therapy in Patients Newly Diagnosed with Human Immunodeficiency Virus
por: Griffith, Kamron Amir, et al.
Publicado: (2023)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

The physical activity levels among people living with human immunodeficiency virus/acquired immunodeficiency syndrome receiving high active antiretroviral therapy in Rwanda
por: Frantz, J.M., et al.
Publicado: (2014)

Potential role of intermittent fasting on decreasing cardiovascular disease in human immunodeficiency virus patients receiving antiretroviral therapy
por: Gnoni, Martin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l9g8n1n48ss9afnvsdrquq9h6h